<DOC>
	<DOCNO>NCT01271751</DOCNO>
	<brief_summary>The purpose study evaluate efficacy GFT505 80mg reduce serum Triglycerides ( TG ) increase High Density Lipoprotein Cholesterol ( HDL-C ) level compare placebo atherogenic dyslipidaemic patient abdominal obesity , assess tolerability safety once-a-day administration oral dos GFT505 28 day .</brief_summary>
	<brief_title>Pilot Study With GFT505 ( 80mg ) Atherogenic Dyslipidaemic Patients With Abdominal Obesity</brief_title>
	<detailed_description>The study period per patient 7 14 week : screening period ( 1 8 week ) precede 4-week double-blind treatment period 2-week follow-up period . During screen period , patient ask start continue adequate diet exercise stop lipid-lowering medication ( treatment-naïve patient ) . For patient take lipid-regulating medication , minimum 8-week wash-out lipid-regulating therapy ( fibrates , statin , … ) require .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<criteria>Male postmenopausal female . Waist circumference ≥102cm male , ≥ 88cm female . Atherogenic dislipidaemia inadequately control despite Therapeutic Lifestyle Change ( TLC ) recommendation ( diet exercise ) . 150≤ fast TG ≤ 600 mg/dL ( 1.69 ≤ fast TG ≤ 6.78 mmol/L ) V2 . Fasting HDLC ≤ 40 mg/dL ( ≤ 1.03 mmol/L ) male , HDLC ≤ 45 mg/dL ( ≤ 1.16 mmol/L ) female V2 . Body Mass Index ( BMI ) ≥ 40 kg/m² . Blood Pressure &gt; 160 / 95 mmHg . Type I type II Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Atherogenic-dyslipidaemia</keyword>
	<keyword>PPARs</keyword>
</DOC>